Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a strong financial turnaround with a net income of $9.2 million compared to a loss last year, positive regulatory feedback, and a growing market opportunity for Revita. The Q&A section reveals confidence in pivotal trial success and enthusiastic physician feedback, offsetting concerns about unclear management responses. Overall, the strategic plan and financial health suggest a positive stock price movement.
Key Financial Performance
Research and Development Expenses $15.6 million for Q1 2026 compared to $19.4 million for the same period in 2025, a decrease primarily related to reduced spending on Revita and Rejuva programs as well as lower personnel-related expenses.
SG&A Expenses $5.2 million for Q1 2026 compared to $5.3 million for the same period in 2025, stable with minimal change.
Net Income $9.2 million for Q1 2026 compared to a net loss of $23.7 million for the same period in 2025, driven by a $30.1 million noncash accounting change in the fair value of warrant liabilities, not reflecting a change in underlying operating performance.
Total Operating Expenses $3.9 million lower in Q1 2026 compared to the same period in 2025.
Adjusted EBITDA Negative $18 million for Q1 2026 compared with negative $23 million in Q1 2025, a decrease primarily due to a decrease in operating expenses.
Cash and Cash Equivalents Approximately $63.2 million as of March 31, 2026, expected to fund operations into early 2027, beyond anticipated pivotal data readout and potential de novo submission.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revita: Revita is being developed as a solution for post-GLP-1 weight regain. The pivotal trial is fully randomized and executing on plan, with the REMAIN-1 pivotal cohort completing randomizations in February 2026. The trial includes over 300 participants across 30+ sites in the U.S. and is the largest sham-controlled GI endoscopy pivotal trial ever conducted. The company plans to deliver top-line 6-month primary endpoint data in early Q4 2026. Regulatory progress includes favorable FDA feedback on device classification and plans for FDA submission in late Q4 2026.
Rejuva: Rejuva is a smart GLP-1 gene therapy platform targeting long-term metabolic remission from a single dose. The first clinical candidate, RJVA-001, received authorization from EU regulatory authorities to initiate a Phase I/II study. The therapy is designed for nutrient-responsive GLP-1 expression within the pancreas and is delivered via minimally invasive endoscopic ultrasound. Preliminary data is expected in the second half of 2026.
Market dynamics for Revita: The market for Revita is favorable due to the growing number of GLP-1 initiators and discontinuers. Approximately 1 million patients discontinue GLP-1s monthly, creating a large potential market for Revita as a durable alternative. Public programs are expanding low-cost access to GLP-1 therapies, particularly for Medicare and Medicaid beneficiaries, which could increase the number of patients needing post-GLP-1 solutions.
RAPID coverage pathway: The CMS and FDA announced the RAPID coverage pathway, which aligns Medicare national coverage with FDA market authorization for eligible breakthrough devices. Revita, holding FDA breakthrough device designation, may benefit from this pathway, potentially accelerating commercialization and reimbursement timelines.
Clinical trial execution: The REMAIN-1 pivotal cohort completed randomizations with over 300 participants and is tracking favorably on all operational metrics. Participant retention exceeds 90%, and medication resumption rates are below modeled assumptions. The study is on track for a Q4 2026 data readout.
Financial management: The company reported a net income of $9.2 million for Q1 2026, driven by a noncash accounting change. Operating expenses decreased by $3.9 million compared to Q1 2025. The cash position of $63.2 million is expected to fund operations into early 2027.
Capital strategy: The company has closed its ATM facility and does not plan to raise capital before pivotal data is available. This decision reflects management's confidence in the pivotal data and alignment with shareholders.
Regulatory and reimbursement strategy: The company is advancing its reimbursement infrastructure, including plans to file a Category III CPT code application in summer 2026 and leveraging transitional pass-through payment mechanisms for hospitals. These efforts aim to ensure a favorable reimbursement pathway for Revita.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Reimbursement Risks: The company is dependent on favorable FDA and CMS decisions for Revita's approval and reimbursement. Any delays or unfavorable outcomes could significantly impact commercialization timelines and financial performance.
Clinical Trial Risks: The success of Revita hinges on the outcomes of ongoing pivotal trials. Any failure to meet endpoints or adverse events could derail regulatory approval and market entry.
Market Dynamics and Competitive Pressures: The introduction of oral GLP-1 therapies and expanding access to GLP-1s through public programs could intensify competition, potentially reducing the market share for Revita.
Financial Risks: The company has a limited cash runway into early 2027. Any unexpected costs or delays in achieving pivotal data could necessitate additional capital raises, contrary to management's current plans.
Operational Risks: The company is heavily reliant on its network of clinical champions and centers of excellence. Any disruptions in these relationships could impact the adoption and success of Revita.
Strategic Execution Risks: The commercialization and reimbursement pathways for Revita are complex and untested. Any missteps in execution could delay market entry or limit adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revita pivotal trial progress: The REMAIN-1 pivotal cohort completed randomizations in February 2026 with over 300 participants across 30+ U.S. sites. The trial is the largest sham-controlled GI endoscopy pivotal trial ever conducted. The study is on track to deliver top-line 6-month primary endpoint data in early Q4 2026, with FDA submission planned for late Q4 2026.
Regulatory and reimbursement pathways: Favorable FDA feedback on Revita's de novo classification request confirms a moderate-risk device classification. The CMS and FDA RAPID coverage pathway may accelerate commercialization and reimbursement timelines. A Category III CPT code application is planned for summer 2026, with effectiveness expected by summer 2027.
Market dynamics and commercial opportunity: The approval of oral GLP-1 therapies and expanded Medicare/Medicaid access to GLP-1s are expected to increase the population facing post-GLP-1 weight regain, enhancing Revita's market potential. Approximately 1 million patients discontinue GLP-1s monthly, creating a significant need for durable alternatives like Revita.
Upcoming data readouts and milestones: Three major Revita data readouts are expected in 2026: 12-month open-label data from REVEAL-1 in Q2, 12-month randomized data from REMAIN-1 midpoint cohort in Q3, and 6-month pivotal data from REMAIN-1 in early Q4. A potential de novo marketing application submission is planned for late Q4 2026.
Rejuva platform development: The RJVA-001 gene therapy candidate has received EU regulatory authorization for a Phase I/II study in the Netherlands, with plans to expand to other European sites and Australia. First patient dosing and preliminary data are expected in H2 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you walk us through the enrollment timelines, target product profile, and expectations for the preliminary data set for Rejuva?
A:Subject to site activation, there is a several-week run-in period for first patients. The study uses a 3x3 design, starting with an initial dose to evaluate safety, feasibility, and initial PK/PD from three individuals before escalating doses. Safety and feasibility signals should be seen within 1-2 weeks of dosing, while preliminary PK and PD signals are expected around 8 weeks after dosing. Updates will be provided after initial safety and feasibility assessments and efficacy signals.
Q:Is an all-comer pivotal success required for de novo submission, or could dose response or subgroup data influence the regulatory package?
A:The de novo pathway has a different clinical threshold than a PMA, focusing on reasonable assurance of safety and effectiveness based on the totality of clinical evidence rather than a single p-value. While flexibility exists, the company is confident in pivotal trial success under any metric.
Q:Are there any updates on German commercial use and insights gained from it?
A:Patients are being followed, with 2-year data reported last year and follow-ups continuing up to 5 years. Updates will be provided once a reasonable number of patients hit 3 years, expected in the coming quarters. This data will show the durability of effect and real-world use of Revita.
Q:Will the de novo marketing application submission include 1-year REVEAL-1 cohort data and 1-year REMAIN-1 midpoint cohort data?
A:Yes, the submission will include all data, including REVEAL-1 and REMAIN-1 midpoint cohort data, contributing to the totality of evidence. The FDA is expected to consider all available evidence for marketing authorization, and the company is confident in its pivotal trial and FDA feedback.
Q:What is the approach for the first dose cohort in the RJVA-001 study?
A:The first dose is an active dose intended to benefit patients. While cautious to ensure safety, the company is optimistic about observing active signals after sufficient time post-administration.
Q:What feedback was received from physicians and clinicians at DDW regarding the advisory board and commercialization plans?
A:Feedback was positive, with enthusiasm from physicians across the U.S. who are leaders in GI endoscopy and metabolic/bariatric endoscopy. The clinical infrastructure and physician relationships built during pivotal studies provide a strong foundation for commercialization.
Q:Were there any material additions or changes to the IP portfolio in the past quarter, including for Rejuva?
A:The IP portfolio was strengthened in Q1, particularly for Revita and Rejuva. The focus is on establishing a strong IP landscape around the device, procedure, and gene therapy product. Specific new patents issued in Q1 were not confirmed but will be followed up.
Q:When should we expect regulatory feedback from additional European countries for the Phase I/II trial of Rejuva?
A:The company has all necessary feedback to initiate the RJVA-001 study in Europe, with the first patients expected to be treated in the Netherlands. Regulatory feedback from Australia is expected in Q3. The FDA has not yet been approached, with plans to secure early safety and feasibility data before engaging.
Q:Review of Unclear Management Responses
A:The management avoided providing specific guidance on when the 3-year data from German commercial use will be available, stating only that it will come in the 'coming quarters.' Additionally, they did not confirm whether any new patents were issued in Q1, promising to follow up on this information.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CMS
DDW
FDA
GI
GLP therapy
GLP weight
RAPID
RJVA
Rejuva
abstract
authorization
body weight
champion
community
coverage
device
effect
endoscopy
endpoint
gene therapy
line month
meeting
metabolic
midpoint cohort
novo
option
participant
pathway
patient
payment
post GLP
readout
regain
run weight
sham
signal
study
trial
weight loss
weight maintenance
GUTS Transcript
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-14
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights a strong financial turnaround with a net income of $9.2 million compared to a loss last year, positive regulatory feedback, and a growing market opportunity for Revita. The Q&A section reveals confidence in pivotal trial success and enthusiastic physician feedback, offsetting concerns about unclear management responses. Overall, the strategic plan and financial health suggest a positive stock price movement.
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call presents mixed signals. Basic financial performance shows decreased R&D expenses but increased SG&A, and a significant noncash net loss. Product development updates are positive, with confidence in pivotal study results. Market strategy faces hurdles with reimbursement pathways. Financial health is stable with cash to fund operations till 2027. Shareholder returns were not discussed. The Q&A reveals positive sentiment towards ablation efficacy but management's avoidance of specifics on secondary endpoints raises concerns. Overall, the mixed financials and strategic uncertainties balance out the positive product developments, leading to a neutral sentiment.
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call presents a mixed but overall positive outlook. The company's strategic initiatives, including the Revita therapy and Rejuva program, show promise with significant weight loss results and ongoing clinical trials. Despite increased net loss due to non-cash accounting changes, the cash position is strong, extending into 2027. The Q&A highlighted consistent weight loss data and ongoing efforts for market preparation. However, the lack of specific guidance on RJVA-002 receptor potency could be a concern. Overall, the positive clinical data and strategic planning outweigh the negatives, suggesting a positive stock reaction.
GUTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
